Regulatory Replimune gets early August decision date for twice-rejected melanoma drug BioSpaceReplimune's resubmission for RP1 for melanoma comes after the departures of FDA leaders in place at the time of the drug's first two rejections.OncologyRead full story pharminent June 26, 2026 (Last updated: June 26, 2026) BioSpace Replimune’s resubmission for RP1 for melanoma comes after the departures of FDA leaders in place at the time of the drug’s first two rejections. Oncology Read full story Post navigation Previous: Moderna looks out to R&D ‘horizons’ as 2028 break-even goal loomsNext: Moderna Maps R&D ‘Horizons’ as 2028 Break-Even Goal Looms Related Stories Regulatory FDA clears Takeda, Protagonist’s first-in-class PV drug pharminent August 31, 2026 Regulatory FDA green lights Priovant drug for rare skin disease pharminent August 28, 2026 Regulatory Neurocrine receives FDA IND Acceptance for Alzheimer’s Ph2 pharminent August 26, 2026